Radboud UMC
Welcome,         Profile    Billing    Logout  
 109 Trials 
242 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tack, Cees J
RAID-II, NCT06422494: The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-

Not yet recruiting
N/A
24
NA
hyperinsulinaemic hypoglycaemic clamp, Propranolol Hydrochloride 1 MG/ML, Phentolamine
Radboud University Medical Center
Diabetes Mellitus, Type 1, Inflammation
09/25
10/25
RAID, NCT05990933: Role of Adrenaline in in the Inflammatory Response in Diabetes

Completed
N/A
30
Europe
Adrenaline, Adrenaline infusion
Cees Tack
Inflammatory Response, Diabetes Type1, Hypoglycemia
09/24
09/24
Burger, David M
UNIVERSALRBA, NCT05489406: Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Completed
1
16
Europe
DTG DT (6 x 5 mg), Tivicay 5 mg (ViiV), F/TAF TOS (3 x 60/7.5 mg), F/TAF TOS 60/7.5 mg (Gilead)
Radboud University Medical Center, Gilead Sciences
Hiv
03/23
11/23
PANNA, NCT00825929 / 2008-006158-16: Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Recruiting
N/A
176
Europe
Radboud University Medical Center, PENTA Foundation, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Janssen Pharmaceutica, ViiV Healthcare, Gilead Sciences
HIV Infections
12/26
12/26
CHRONO, NCT04888754: A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands

Active, not recruiting
N/A
35
Europe
Erasmus Medical Center
HIV Infections, HIV-1-infection, HIV-2 Infection
01/27
01/34
Pickkers, Peter
DEDICATE-LPS, NCT06624436: Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Not yet recruiting
4
52
Europe
Dexamethasone, Tocilizumab, RoActemra, Tyenne, Anakinra, Kineret, Placebo, NaCl 0.9%, LPS, Endotoxin, Lipopolysaccharide (LPS from E. coli type O113)
Radboud University Medical Center
Sepsis, Neuroinflammatory Response, Immunosuppresion, Endotoxemia, Anakinra, Dexamethasone, Tocilizumab
05/25
07/25
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT04612413: A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Active, not recruiting
2
160
Europe, RoW
Allocetra-OTS, Placebo
Enlivex Therapeutics Ltd., Cato Research, Accelsiors CRO & Consultancy Services
Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections
12/24
03/25
NCT06331884: Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

Completed
1
24
Europe
AK1967 (Procizumab), Placebo
4TEEN4 Pharmaceuticals GmbH
Safety and Tolerability
08/24
09/24
REMEDI, NCT03939273: The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery

Not yet recruiting
N/A
80
Europe
Vancomycin Oral, Metronidazole Oral, Ciprofloxacin Pill, Fluconazole Oral Product, Placebos
Radboud University Medical Center
Systemic Inflammatory Response Syndrome, Postoperative Shock, Coronary Artery Disease, Extracorporeal Circulation; Complications
03/23
03/23
Wiegand, Jan A
FICUS, NCT05280691: Family Support Intervention in Intensive Care Units

Active, not recruiting
N/A
885
Europe
Family Support Intervention (FSI)
Rahel Naef, Swiss National Science Foundation
Postintensive Care Syndrome, Family Members, Quality of Life, Depression, Anxiety, Posttraumatic Stress Disorder, Family Dynamics
03/24
12/25
CIBOSurg, NCT05818332: ClassIntra® for Better Outcomes in Surgery -

Recruiting
N/A
1800
Europe
Observational study
University Hospital, Basel, Switzerland
Perioperative Patient Safety
12/25
07/27
Kessels, L
DIRECT-2, NCT05503108: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Suspended
3
10
Europe
Fasting Mimicking diet program, Xentigen™
Leiden University Medical Center, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, World Cancer Research Fund International, L-Nutra Inc
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response, Objective Response Rate, Neoadjuvant Chemotherapy
01/24
01/24
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer

Recruiting
2
130
Europe
Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex
Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
12/24
03/28
OPTImaL, NCT06476119: Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Not yet recruiting
N/A
490
Europe
Adjuvant chemotherapy, according to local/ national guidelines, No adjuvant chemotherapy
The Netherlands Cancer Institute, Maarten van de Weijden Foundation, AVL Foundation
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
09/32
09/34
Herpen, CML van
DUCT, NCT05513365: Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting
2
26
Europe
Goserelin 10.8 mg, Zoladex, Bicalutamide 50 mg, Casodex, Dutasteride 0.5 mg, Avodart
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Salivary Duct Carcinoma
09/25
09/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Heesakkers, John
GETSBI, NCT05518864: GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis ( Study)

Recruiting
4
80
Europe
IALURIL Prefill
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, IQ Healthcare, Radboud Technology Ceter, Zorginstituut Nederland
Bladder Pain Syndrome
10/24
10/24
OASIS, NCT03596671: BlueWind RENOVA iStim™ System for the Treatment of OAB

Recruiting
N/A
200
Europe, US
RENOVA iStim™ System
BlueWind Medical
Treatment of Patients Suffering From Overactive Bladder (OAB)
10/22
01/25
NCT05874375: UCon Treatment of Overactive Bladder (OAB) in Males

Recruiting
N/A
20
Europe
Urge stimulation, DGN stimulation, Neurostimulation, Time limited stimulation
InnoCon Medical
Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night, Urinary Incontinence, Urge, Incontinence, Nighttime Urinary
06/25
06/25
SATURN, NCT02757274: Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence

Active, not recruiting
N/A
1054
Europe, RoW
European Association of Urology Research Foundation, Boston Scientific Corporation
Urinary Incontinence, Stress
02/27
07/27
Drenth, Joost PH
CAMARO, NCT02900443: Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

Active, not recruiting
4
70
Europe
Mycophenolate mofetil, Azathioprine
Radboud University Medical Center, Leiden University Medical Center
Autoimmune Hepatitis
06/23
06/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
ATLAS, NCT05500157: Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts

Recruiting
N/A
70
Europe
aspiration sclerotherapy versus laparoscopic fenestration
Radboud University Medical Center
Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
10/23
10/24
NCT02173080: Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

Completed
N/A
594
US
PLD-Q
Mayo Clinic
Polycystic Liver Disease
03/24
03/24
PLD, NCT04645251: Polycystic Liver Disease Registry (UK)

Recruiting
N/A
500
Europe
Portsmouth Hospitals NHS Trust, Radboud University Medical Center
Polycystic Liver Disease
12/30
12/30
Goor, Harry van
NCT00882167: Cine-magnetic Resonance Imaging (MRI) Detecting Intra Abdominal Adhesions

Recruiting
N/A
100
Europe
CineMRI
Radboud University Medical Center
Tissue Adhesions
12/25
12/25
CIBOSurg, NCT05818332: ClassIntra® for Better Outcomes in Surgery -

Recruiting
N/A
1800
Europe
Observational study
University Hospital, Basel, Switzerland
Perioperative Patient Safety
12/25
07/27
Kroep, J R
Subito, NCT02810743 / 2016-002493-13: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Active, not recruiting
3
174
Europe
ddAC-CP-Olaparib, ddAC-mini CTC
The Netherlands Cancer Institute
Breast Cancer
10/24
12/33
FUTURE, NCT06193525: FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Recruiting
2
66
Europe
Talazoparib, Talazoparib 1 MG Oral Capsule [Talzenna]
Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen
Advanced Breast Cancer
12/25
12/25
FAB, NCT04780945 / 2018-001660-29: Functional Analysis of BRCAness

Recruiting
2
55
Europe
Functional RAD51 assay, RECAP assay, Olaparib Oral Product, Olaparib tablet
Leiden University Medical Center, Erasmus Medical Center, University Medical Center Groningen
Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation
12/22
06/23
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
OPTImaL, NCT06476119: Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Not yet recruiting
N/A
490
Europe
Adjuvant chemotherapy, according to local/ national guidelines, No adjuvant chemotherapy
The Netherlands Cancer Institute, Maarten van de Weijden Foundation, AVL Foundation
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
09/32
09/34
NCT00330447: Effects of Oncological Treatment During Pregnancy on Mother and Child

Recruiting
N/A
5000
Europe, US, RoW
University Hospital, Gasthuisberg, The Netherlands Cancer Institute, Erasmus Medical Center, San Gerardo Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Charles University, Czech Republic
Cancer, Pregnancy
04/25
12/32
Royen, N van
POPular PAUSE TAVI, NCT04437303 / 2020-001817-20: Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation

Completed
4
858
Europe
Continuation of oral anticoagulants, Interruption of oral anticoagulants
St. Antonius Hospital
Aortic Valve Disease, Aortic Valve Stenosis, Stroke, Bleeding, Vascular Complications, Myocardial Infarction, Thrombosis Embolism
03/24
05/24
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
PAT-CHINA-303, NCT05136664: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Recruiting
3
200
RoW
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B)
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Hyperkalemia, Renal Insufficiency, Chronic
06/25
09/25
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
06/24
05/25
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Terminated
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
12/24
12/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
AAT, Alpha-1 proteinase inhibitor, Respreeza, Placebo
CSL Behring, Commercial/Industry, CSL
Acute-graft-versus-host Disease
04/28
10/29
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
12/25
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
Canada, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed
1
10
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
09/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed
1
12
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
10/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Disease Driven by Complement Activation
04/25
04/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Herpen, Carla van
LUPSA, NCT04291300: Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Completed
2
12
Europe
Lutetium-177-PSMA-I&T, Lutetium-177 Prostate Specific Membrane Antigen
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma
02/23
02/23
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
DUCT, NCT05513365: Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting
2
26
Europe
Goserelin 10.8 mg, Zoladex, Bicalutamide 50 mg, Casodex, Dutasteride 0.5 mg, Avodart
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Salivary Duct Carcinoma
09/25
09/27
COMMENCE, NCT02054442 / 2013-002886-20: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

Active, not recruiting
1/2
52
Europe
Cetuximab, Erbitux, L01XC06, Methotrexate, EMTHEXATE, L01BA01
Radboud University Medical Center, Merck Serono International SA, Leiden University Medical Center, Academisch Ziekenhuis Maastricht, Erasmus Medical Center, Medisch Spectrum Twente, Medical Center Haaglanden, Elisabeth-TweeSteden Ziekenhuis, Medical Centre Leeuwarden
Squamous Cell Carcinoma of the Head and Neck
12/21
12/22
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
SYLVER, NCT06710847: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Recruiting
1/2
73
Japan, US
GSK4418959, PD-1 inhibitor
GlaxoSmithKline, IDEAYA Biosciences
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
02/27
06/28
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
BYON3521.001, NCT05323045: A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Active, not recruiting
1
31
Europe
BYON3521
Byondis B.V.
Solid Tumor
07/24
07/24
ADT-SCAN, NCT04214353: PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Recruiting
N/A
14
Europe
68Ga-PSMA-PET/CT, 18FDG-PET/CT
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma
05/23
09/23
Verheul, Henk MW
SUNRISE-CRC, NCT03909724: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Recruiting
2/3
60
Europe
Sunitinib Malate, Sutent, TAS 102, Lonsurf
Amsterdam UMC, location VUmc
Colorectal Cancer, Metastasis
07/21
07/22
CAIRO6, NCT02758951 / 2016-001865-99: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

Active, not recruiting
2/3
358
Europe
Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab, Perioperative FOLFIRI-bevacizumab, CRS-HIPEC, experimental arm, CRS-HIPEC, control arm
Koen Rovers, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Hoffmann-La Roche
Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma, Colorectal Adenocarcinoma, Peritoneal Neoplasms, Peritoneal Carcinomatosis, Peritoneal Cancer, Peritoneal Metastases, Peritoneal Neoplasm Malignant Secondary Carcinomatosis, Peritoneal Neoplasm Malignant Secondary
10/24
06/29
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT04954599 / 2021-000423-12: Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting
1/2
126
Europe
CP-506, HAP CP-506, Carboplatin, Paraplatin, Immune checkpoint inhibitor, Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Cemiplimab
Maastricht University Medical Center, Erasmus Medical Center, Jules Bordet Institute, Academisch Ziekenhuis Maastricht
Unspecified Adult Solid Tumor, Protocol Specific
02/26
05/26
Wilt, JHW de
MIRCA & MIPAC, NCT06395337: Multimodal Imaging in Rectal Cancer & Pancreatic Cancer

Not yet recruiting
1/2
20
Europe
[111In]In-DOTA-ANTI-CEA antibody injection, SPECT/CT scan, Resection surgery
Radboud University Medical Center, Leiden University Medical Center
Rectal Cancer, Pancreatic Cancer
05/25
06/25
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
HOFLAND, Jan
DESIGNATION, NCT03884543: Driving Pressure During General Anesthesia for Open Abdominal Surgery

Active, not recruiting
N/A
1468
Europe
Individualized high PEEP strategy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam UMC, location VUmc, Noord West Ziekenhuizen location Alkmaar, University Medical Center Groningen, Radboud University Medical Center, HagaZiekenhuis, Rijnstate Hospital, Medical Center Haaglanden, Bernhoven Hospital, Onze Lieve Vrouwe Gasthuis, Albert Schweitzer Hospital, Medical Centre Leeuwarden, Leiden University Medical Center, Maastricht University Medical Center, Martini Hospital Groningen, Erasmus Medical Center, Spaarne Gasthuis, University Hospital Carl Gustav Carus, Bermanntrost BG Klinikum Halle, Heinrich-Heine University, Duesseldorf, Ospedale Policlinico San Martino, Jeroen Bosch Ziekenhuis, Meander Medical Center, Isala, Alrijne Hospital, Antoni van Leeuwenhoek Ziekenhuis, Medisch Spectrum Twente, Campus Bio-Medico University, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, University of Roma La Sapienza, University of Campania Luigi Vanvitelli, Hospital Universitario La Fe, Medical University Innsbruck
Postoperative Respiratory Complication
12/24
06/25
Nyberg, Andre
NCT03518723: Effect and Feasibility of Non-linear Periodized Resistance Training in People With COPD

Completed
N/A
57
Europe, Canada
Non-linear Periodized Resistance Training, Resistance training
Umeå University, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Radboud University Medical Center, Merem Pulmonary Rehabilitation Centre
Pulmonary Disease, Chronic Obstructive
03/23
03/23
COPD-HIIT-AC, NCT05874999: Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD

Completed
N/A
32
Europe
Supramaximal High-Intensity Interval Training at 60% of MPO6, Supramaximal High-Intensity Interval Training at 60% of MPO6 (HIIT60%), Moderate-Intensity Continuous Training, MICT, Supramaximal High-Intensity Interval Training at 80% of MPO6, Supramaximal High-Intensity Interval Training at 80% of MPO6 (HIIT80%)
Umeå University, The Swedish Research Council, Swedish Heart Lung Foundation, Riksförbundet HjärtLung
COPD, Healthy Older Adults
12/22
12/22
COPD-HIIT, NCT06068322: Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease

Recruiting
N/A
208
Europe
Exercise training on a stationary bicycle
Umeå University, Hasselt University, Swedish Heart Lung Foundation, European Research Council, The Swedish Research Council, Ziekenhuis Oost-Limburg, Strategic Research Area - Health Care Science
COPD, Healthy Controls
12/28
12/28
Heuvel, Michel M van den
IMPROVE-I, NCT03656549: Dose Individualization of Pemetrexed -

Completed
4
6
Europe
Pemetrexed + oral folinic acid rescue
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Non Small Cell Lung Cancer, Mesothelioma
12/23
12/23
DEDICATION-1, NCT04909684 / 2020-000493-15: Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Recruiting
3
750
Europe
Pembrolizumab
Radboud University Medical Center, Dutch Society of Physicians for Pulmonology and Tuberculosis
NSCLC
11/24
11/24
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NVALT28, NCT04597671: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC

Active, not recruiting
3
170
Europe
Durvalumab, Imfinzi, low-dose PCI, Prophylactic Cranial Irradiation (PCI)
Association NVALT Studies
Carcinoma, Non-Small-Cell Lung
12/28
12/32
IMPRINT, NCT06218069: Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Not yet recruiting
2/3
20
Europe
Sasanlimab, humanized hinge region-stabilized IgG4 monoclonal anti-PD1 antibody, PF-06801591, non-ablative radiotherapy, [89Zr]Zr-crefmirlimab berdoxam
Radboud University Medical Center, Pfizer, ImaginAb, Inc., University Hospital Tuebingen
NSCLC
12/25
03/27
Wilt, H JW de
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer

Completed
3
206
Europe
Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules
Dutch Colorectal Cancer Group, Hoffmann-La Roche
Colon Cancer, Primary Tumour, Rectal Cancer
06/22
12/22
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases

Completed
3
530
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
07/22
01/25
Verheul, HMW
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases

Completed
3
530
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
07/22
01/25
ORCHESTRA, NCT01792934: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recruiting
N/A
478
Europe
XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy
Radboud University Medical Center, Erasmus Medical Center
Multi-organ Metastatic Colorectal Cancer
07/23
07/25
EMOCA, NCT05062447: Adaptive and Maladaptive Emotions in Patients With Cancer: Identification of Indicators

Terminated
N/A
134
Europe
Amsterdam UMC, location VUmc, Dutch Cancer Society
Adaptation, Emotional
05/24
05/24
Rutten, H
NCT03659448 / 2018-000151-40: Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Recruiting
3
300
Europe, US
SGM-101
Surgimab
Colorectal Neoplasms
11/24
12/24
MODELS, NCT06366828: Prediction Models for Complications After CRT in Esophageal Cancer

Recruiting
N/A
2000
Europe
retrospective
University Medical Center Groningen, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Dutch Institute for Clinical Auditing (DICA), ZorgTTP
The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)
06/25
06/30
Cortot, Alexis
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Recruiting
2
149
Europe
Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
Centre Francois Baclesse, GFPC
NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation
10/21
06/25
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

Active, not recruiting
2
150
Europe
TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis
Nantes University Hospital, AstraZeneca
Non-small Cell Lung Cancer
01/25
01/25
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tack, Cees J
RAID-II, NCT06422494: The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-

Not yet recruiting
N/A
24
NA
hyperinsulinaemic hypoglycaemic clamp, Propranolol Hydrochloride 1 MG/ML, Phentolamine
Radboud University Medical Center
Diabetes Mellitus, Type 1, Inflammation
09/25
10/25
RAID, NCT05990933: Role of Adrenaline in in the Inflammatory Response in Diabetes

Completed
N/A
30
Europe
Adrenaline, Adrenaline infusion
Cees Tack
Inflammatory Response, Diabetes Type1, Hypoglycemia
09/24
09/24
Burger, David M
UNIVERSALRBA, NCT05489406: Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Completed
1
16
Europe
DTG DT (6 x 5 mg), Tivicay 5 mg (ViiV), F/TAF TOS (3 x 60/7.5 mg), F/TAF TOS 60/7.5 mg (Gilead)
Radboud University Medical Center, Gilead Sciences
Hiv
03/23
11/23
PANNA, NCT00825929 / 2008-006158-16: Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Recruiting
N/A
176
Europe
Radboud University Medical Center, PENTA Foundation, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Janssen Pharmaceutica, ViiV Healthcare, Gilead Sciences
HIV Infections
12/26
12/26
CHRONO, NCT04888754: A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands

Active, not recruiting
N/A
35
Europe
Erasmus Medical Center
HIV Infections, HIV-1-infection, HIV-2 Infection
01/27
01/34
Pickkers, Peter
DEDICATE-LPS, NCT06624436: Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Not yet recruiting
4
52
Europe
Dexamethasone, Tocilizumab, RoActemra, Tyenne, Anakinra, Kineret, Placebo, NaCl 0.9%, LPS, Endotoxin, Lipopolysaccharide (LPS from E. coli type O113)
Radboud University Medical Center
Sepsis, Neuroinflammatory Response, Immunosuppresion, Endotoxemia, Anakinra, Dexamethasone, Tocilizumab
05/25
07/25
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT04612413: A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Active, not recruiting
2
160
Europe, RoW
Allocetra-OTS, Placebo
Enlivex Therapeutics Ltd., Cato Research, Accelsiors CRO & Consultancy Services
Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections
12/24
03/25
NCT06331884: Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

Completed
1
24
Europe
AK1967 (Procizumab), Placebo
4TEEN4 Pharmaceuticals GmbH
Safety and Tolerability
08/24
09/24
REMEDI, NCT03939273: The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery

Not yet recruiting
N/A
80
Europe
Vancomycin Oral, Metronidazole Oral, Ciprofloxacin Pill, Fluconazole Oral Product, Placebos
Radboud University Medical Center
Systemic Inflammatory Response Syndrome, Postoperative Shock, Coronary Artery Disease, Extracorporeal Circulation; Complications
03/23
03/23
Wiegand, Jan A
FICUS, NCT05280691: Family Support Intervention in Intensive Care Units

Active, not recruiting
N/A
885
Europe
Family Support Intervention (FSI)
Rahel Naef, Swiss National Science Foundation
Postintensive Care Syndrome, Family Members, Quality of Life, Depression, Anxiety, Posttraumatic Stress Disorder, Family Dynamics
03/24
12/25
CIBOSurg, NCT05818332: ClassIntra® for Better Outcomes in Surgery -

Recruiting
N/A
1800
Europe
Observational study
University Hospital, Basel, Switzerland
Perioperative Patient Safety
12/25
07/27
Kessels, L
DIRECT-2, NCT05503108: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Suspended
3
10
Europe
Fasting Mimicking diet program, Xentigen™
Leiden University Medical Center, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, World Cancer Research Fund International, L-Nutra Inc
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response, Objective Response Rate, Neoadjuvant Chemotherapy
01/24
01/24
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer

Recruiting
2
130
Europe
Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex
Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
12/24
03/28
OPTImaL, NCT06476119: Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Not yet recruiting
N/A
490
Europe
Adjuvant chemotherapy, according to local/ national guidelines, No adjuvant chemotherapy
The Netherlands Cancer Institute, Maarten van de Weijden Foundation, AVL Foundation
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
09/32
09/34
Herpen, CML van
DUCT, NCT05513365: Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting
2
26
Europe
Goserelin 10.8 mg, Zoladex, Bicalutamide 50 mg, Casodex, Dutasteride 0.5 mg, Avodart
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Salivary Duct Carcinoma
09/25
09/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Heesakkers, John
GETSBI, NCT05518864: GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis ( Study)

Recruiting
4
80
Europe
IALURIL Prefill
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, IQ Healthcare, Radboud Technology Ceter, Zorginstituut Nederland
Bladder Pain Syndrome
10/24
10/24
OASIS, NCT03596671: BlueWind RENOVA iStim™ System for the Treatment of OAB

Recruiting
N/A
200
Europe, US
RENOVA iStim™ System
BlueWind Medical
Treatment of Patients Suffering From Overactive Bladder (OAB)
10/22
01/25
NCT05874375: UCon Treatment of Overactive Bladder (OAB) in Males

Recruiting
N/A
20
Europe
Urge stimulation, DGN stimulation, Neurostimulation, Time limited stimulation
InnoCon Medical
Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night, Urinary Incontinence, Urge, Incontinence, Nighttime Urinary
06/25
06/25
SATURN, NCT02757274: Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence

Active, not recruiting
N/A
1054
Europe, RoW
European Association of Urology Research Foundation, Boston Scientific Corporation
Urinary Incontinence, Stress
02/27
07/27
Drenth, Joost PH
CAMARO, NCT02900443: Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

Active, not recruiting
4
70
Europe
Mycophenolate mofetil, Azathioprine
Radboud University Medical Center, Leiden University Medical Center
Autoimmune Hepatitis
06/23
06/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
ATLAS, NCT05500157: Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts

Recruiting
N/A
70
Europe
aspiration sclerotherapy versus laparoscopic fenestration
Radboud University Medical Center
Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
10/23
10/24
NCT02173080: Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

Completed
N/A
594
US
PLD-Q
Mayo Clinic
Polycystic Liver Disease
03/24
03/24
PLD, NCT04645251: Polycystic Liver Disease Registry (UK)

Recruiting
N/A
500
Europe
Portsmouth Hospitals NHS Trust, Radboud University Medical Center
Polycystic Liver Disease
12/30
12/30
Goor, Harry van
NCT00882167: Cine-magnetic Resonance Imaging (MRI) Detecting Intra Abdominal Adhesions

Recruiting
N/A
100
Europe
CineMRI
Radboud University Medical Center
Tissue Adhesions
12/25
12/25
CIBOSurg, NCT05818332: ClassIntra® for Better Outcomes in Surgery -

Recruiting
N/A
1800
Europe
Observational study
University Hospital, Basel, Switzerland
Perioperative Patient Safety
12/25
07/27
Kroep, J R
Subito, NCT02810743 / 2016-002493-13: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Active, not recruiting
3
174
Europe
ddAC-CP-Olaparib, ddAC-mini CTC
The Netherlands Cancer Institute
Breast Cancer
10/24
12/33
FUTURE, NCT06193525: FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Recruiting
2
66
Europe
Talazoparib, Talazoparib 1 MG Oral Capsule [Talzenna]
Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen
Advanced Breast Cancer
12/25
12/25
FAB, NCT04780945 / 2018-001660-29: Functional Analysis of BRCAness

Recruiting
2
55
Europe
Functional RAD51 assay, RECAP assay, Olaparib Oral Product, Olaparib tablet
Leiden University Medical Center, Erasmus Medical Center, University Medical Center Groningen
Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation
12/22
06/23
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
OPTImaL, NCT06476119: Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Not yet recruiting
N/A
490
Europe
Adjuvant chemotherapy, according to local/ national guidelines, No adjuvant chemotherapy
The Netherlands Cancer Institute, Maarten van de Weijden Foundation, AVL Foundation
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
09/32
09/34
NCT00330447: Effects of Oncological Treatment During Pregnancy on Mother and Child

Recruiting
N/A
5000
Europe, US, RoW
University Hospital, Gasthuisberg, The Netherlands Cancer Institute, Erasmus Medical Center, San Gerardo Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Charles University, Czech Republic
Cancer, Pregnancy
04/25
12/32
Royen, N van
POPular PAUSE TAVI, NCT04437303 / 2020-001817-20: Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation

Completed
4
858
Europe
Continuation of oral anticoagulants, Interruption of oral anticoagulants
St. Antonius Hospital
Aortic Valve Disease, Aortic Valve Stenosis, Stroke, Bleeding, Vascular Complications, Myocardial Infarction, Thrombosis Embolism
03/24
05/24
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
PAT-CHINA-303, NCT05136664: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Recruiting
3
200
RoW
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B)
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Hyperkalemia, Renal Insufficiency, Chronic
06/25
09/25
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
06/24
05/25
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Terminated
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
12/24
12/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
11/26
11/26
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
AAT, Alpha-1 proteinase inhibitor, Respreeza, Placebo
CSL Behring, Commercial/Industry, CSL
Acute-graft-versus-host Disease
04/28
10/29
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
12/25
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
Canada, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed
1
10
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
09/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed
1
12
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
10/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Disease Driven by Complement Activation
04/25
04/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Herpen, Carla van
LUPSA, NCT04291300: Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Completed
2
12
Europe
Lutetium-177-PSMA-I&T, Lutetium-177 Prostate Specific Membrane Antigen
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma
02/23
02/23
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
DUCT, NCT05513365: Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting
2
26
Europe
Goserelin 10.8 mg, Zoladex, Bicalutamide 50 mg, Casodex, Dutasteride 0.5 mg, Avodart
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Salivary Duct Carcinoma
09/25
09/27
COMMENCE, NCT02054442 / 2013-002886-20: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

Active, not recruiting
1/2
52
Europe
Cetuximab, Erbitux, L01XC06, Methotrexate, EMTHEXATE, L01BA01
Radboud University Medical Center, Merck Serono International SA, Leiden University Medical Center, Academisch Ziekenhuis Maastricht, Erasmus Medical Center, Medisch Spectrum Twente, Medical Center Haaglanden, Elisabeth-TweeSteden Ziekenhuis, Medical Centre Leeuwarden
Squamous Cell Carcinoma of the Head and Neck
12/21
12/22
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
SYLVER, NCT06710847: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Recruiting
1/2
73
Japan, US
GSK4418959, PD-1 inhibitor
GlaxoSmithKline, IDEAYA Biosciences
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
02/27
06/28
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
BYON3521.001, NCT05323045: A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Active, not recruiting
1
31
Europe
BYON3521
Byondis B.V.
Solid Tumor
07/24
07/24
ADT-SCAN, NCT04214353: PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Recruiting
N/A
14
Europe
68Ga-PSMA-PET/CT, 18FDG-PET/CT
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma
05/23
09/23
Verheul, Henk MW
SUNRISE-CRC, NCT03909724: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Recruiting
2/3
60
Europe
Sunitinib Malate, Sutent, TAS 102, Lonsurf
Amsterdam UMC, location VUmc
Colorectal Cancer, Metastasis
07/21
07/22
CAIRO6, NCT02758951 / 2016-001865-99: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

Active, not recruiting
2/3
358
Europe
Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab, Perioperative FOLFIRI-bevacizumab, CRS-HIPEC, experimental arm, CRS-HIPEC, control arm
Koen Rovers, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Hoffmann-La Roche
Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma, Colorectal Adenocarcinoma, Peritoneal Neoplasms, Peritoneal Carcinomatosis, Peritoneal Cancer, Peritoneal Metastases, Peritoneal Neoplasm Malignant Secondary Carcinomatosis, Peritoneal Neoplasm Malignant Secondary
10/24
06/29
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT04954599 / 2021-000423-12: Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting
1/2
126
Europe
CP-506, HAP CP-506, Carboplatin, Paraplatin, Immune checkpoint inhibitor, Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Cemiplimab
Maastricht University Medical Center, Erasmus Medical Center, Jules Bordet Institute, Academisch Ziekenhuis Maastricht
Unspecified Adult Solid Tumor, Protocol Specific
02/26
05/26
Wilt, JHW de
MIRCA & MIPAC, NCT06395337: Multimodal Imaging in Rectal Cancer & Pancreatic Cancer

Not yet recruiting
1/2
20
Europe
[111In]In-DOTA-ANTI-CEA antibody injection, SPECT/CT scan, Resection surgery
Radboud University Medical Center, Leiden University Medical Center
Rectal Cancer, Pancreatic Cancer
05/25
06/25
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
HOFLAND, Jan
DESIGNATION, NCT03884543: Driving Pressure During General Anesthesia for Open Abdominal Surgery

Active, not recruiting
N/A
1468
Europe
Individualized high PEEP strategy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam UMC, location VUmc, Noord West Ziekenhuizen location Alkmaar, University Medical Center Groningen, Radboud University Medical Center, HagaZiekenhuis, Rijnstate Hospital, Medical Center Haaglanden, Bernhoven Hospital, Onze Lieve Vrouwe Gasthuis, Albert Schweitzer Hospital, Medical Centre Leeuwarden, Leiden University Medical Center, Maastricht University Medical Center, Martini Hospital Groningen, Erasmus Medical Center, Spaarne Gasthuis, University Hospital Carl Gustav Carus, Bermanntrost BG Klinikum Halle, Heinrich-Heine University, Duesseldorf, Ospedale Policlinico San Martino, Jeroen Bosch Ziekenhuis, Meander Medical Center, Isala, Alrijne Hospital, Antoni van Leeuwenhoek Ziekenhuis, Medisch Spectrum Twente, Campus Bio-Medico University, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, University of Roma La Sapienza, University of Campania Luigi Vanvitelli, Hospital Universitario La Fe, Medical University Innsbruck
Postoperative Respiratory Complication
12/24
06/25
Nyberg, Andre
NCT03518723: Effect and Feasibility of Non-linear Periodized Resistance Training in People With COPD

Completed
N/A
57
Europe, Canada
Non-linear Periodized Resistance Training, Resistance training
Umeå University, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Radboud University Medical Center, Merem Pulmonary Rehabilitation Centre
Pulmonary Disease, Chronic Obstructive
03/23
03/23
COPD-HIIT-AC, NCT05874999: Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD

Completed
N/A
32
Europe
Supramaximal High-Intensity Interval Training at 60% of MPO6, Supramaximal High-Intensity Interval Training at 60% of MPO6 (HIIT60%), Moderate-Intensity Continuous Training, MICT, Supramaximal High-Intensity Interval Training at 80% of MPO6, Supramaximal High-Intensity Interval Training at 80% of MPO6 (HIIT80%)
Umeå University, The Swedish Research Council, Swedish Heart Lung Foundation, Riksförbundet HjärtLung
COPD, Healthy Older Adults
12/22
12/22
COPD-HIIT, NCT06068322: Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease

Recruiting
N/A
208
Europe
Exercise training on a stationary bicycle
Umeå University, Hasselt University, Swedish Heart Lung Foundation, European Research Council, The Swedish Research Council, Ziekenhuis Oost-Limburg, Strategic Research Area - Health Care Science
COPD, Healthy Controls
12/28
12/28
Heuvel, Michel M van den
IMPROVE-I, NCT03656549: Dose Individualization of Pemetrexed -

Completed
4
6
Europe
Pemetrexed + oral folinic acid rescue
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Non Small Cell Lung Cancer, Mesothelioma
12/23
12/23
DEDICATION-1, NCT04909684 / 2020-000493-15: Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Recruiting
3
750
Europe
Pembrolizumab
Radboud University Medical Center, Dutch Society of Physicians for Pulmonology and Tuberculosis
NSCLC
11/24
11/24
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NVALT28, NCT04597671: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC

Active, not recruiting
3
170
Europe
Durvalumab, Imfinzi, low-dose PCI, Prophylactic Cranial Irradiation (PCI)
Association NVALT Studies
Carcinoma, Non-Small-Cell Lung
12/28
12/32
IMPRINT, NCT06218069: Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Not yet recruiting
2/3
20
Europe
Sasanlimab, humanized hinge region-stabilized IgG4 monoclonal anti-PD1 antibody, PF-06801591, non-ablative radiotherapy, [89Zr]Zr-crefmirlimab berdoxam
Radboud University Medical Center, Pfizer, ImaginAb, Inc., University Hospital Tuebingen
NSCLC
12/25
03/27
Wilt, H JW de
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer

Completed
3
206
Europe
Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules
Dutch Colorectal Cancer Group, Hoffmann-La Roche
Colon Cancer, Primary Tumour, Rectal Cancer
06/22
12/22
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases

Completed
3
530
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
07/22
01/25
Verheul, HMW
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases

Completed
3
530
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
07/22
01/25
ORCHESTRA, NCT01792934: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recruiting
N/A
478
Europe
XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy
Radboud University Medical Center, Erasmus Medical Center
Multi-organ Metastatic Colorectal Cancer
07/23
07/25
EMOCA, NCT05062447: Adaptive and Maladaptive Emotions in Patients With Cancer: Identification of Indicators

Terminated
N/A
134
Europe
Amsterdam UMC, location VUmc, Dutch Cancer Society
Adaptation, Emotional
05/24
05/24
Rutten, H
NCT03659448 / 2018-000151-40: Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Recruiting
3
300
Europe, US
SGM-101
Surgimab
Colorectal Neoplasms
11/24
12/24
MODELS, NCT06366828: Prediction Models for Complications After CRT in Esophageal Cancer

Recruiting
N/A
2000
Europe
retrospective
University Medical Center Groningen, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Dutch Institute for Clinical Auditing (DICA), ZorgTTP
The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)
06/25
06/30
Cortot, Alexis
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Recruiting
2
149
Europe
Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
Centre Francois Baclesse, GFPC
NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation
10/21
06/25
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

Active, not recruiting
2
150
Europe
TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis
Nantes University Hospital, AstraZeneca
Non-small Cell Lung Cancer
01/25
01/25
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
 

Download Options